Literature DB >> 2412130

Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies.

N Kartner, D Evernden-Porelle, G Bradley, V Ling.   

Abstract

One reason for the failure of chemotherapy in the treatment of advanced cancers may be the outgrowth of multidrug-resistant tumour cells. Multidrug resistance has been modelled in numerous mammalian cell lines in which the phenotype is characterized by a pleiotropic cross-resistance to unrelated drugs. In the study reported here, we have produced monoclonal antibodies whose binding to plasma membranes of different multidrug-resistant mammalian cells correlates with the degree of drug resistance. All these antibodies are specific for P-glycoprotein, a cell surface component of relative molecular mass (Mr) 170,000 (170K) that has been described previously, and are directed against three spatially distinct epitopes which define a conserved cytoplasmic domain in the C-terminal region of the P-glycoprotein polypeptide. The conserved nature of P-glycoprotein and its low-level expression is drug-sensitive cells suggest that it has an important function at the cell surface. The monoclonal antibodies against P-glycoprotein described here might serve as diagnostic reagents for clinically unresponsive tumours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412130     DOI: 10.1038/316820a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  182 in total

1.  Multidrug resistance increment in a human colon carcinoma cell line by colchicine.

Authors:  M J Ruiz Gómez; L Gil; A Souviron; M Martínez Morillo
Journal:  J Physiol Biochem       Date:  2000-03       Impact factor: 4.158

2.  Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine.

Authors:  J Hofmann; A Wolf; M Spitaler; G Böck; J Drach; C Ludescher; H Grunicke
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 3.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

5.  Differential expression of folate receptor-alpha, sodium-dependent multivitamin transporter, and amino acid transporter (B (0, +)) in human retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cell lines.

Authors:  Jwala Jwala; Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Sai Hanuman Sagar Boddu; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-03       Impact factor: 2.671

Review 6.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

7.  P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine.

Authors:  M J Ruiz-Gómez; A Souviron; M Martínez-Morillo; L Gil
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

8.  In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug.

Authors:  Sai H S Boddu; Jwala Jwala; Monica R Chowdhury; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

9.  Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila.

Authors:  Fahima Mayer; Nasima Mayer; Leslie Chinn; Robert L Pinsonneault; Deanna Kroetz; Roland J Bainton
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

Review 10.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.